Hunan Er-Kang Pharmaceutical Co Ltd

Hunan Er-Kang Pharmaceutical Co Ltd has a market capitalization of CNY 9.24 billion and a price-to-book ratio of 2.29, indicating that the market values the company at a premium to its book value. The company's liquidity position is assessed as medium, with a current ratio of 2.23, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at CNY -395.34 million, and its operating cash flow is CNY 257.68 million, indicating that it is not generating enough cash from operations to fund its capital expenditures. The company's profitability is weak, with a net loss of CNY -379.82 million and an operating loss of CNY -365.97 million. Its return on equity is -9.41%, and its return on assets is -7.81%, both significantly below the industry median for pharmaceutical companies. The gross profit margin is 22.4%, which is in line with the industry average, but the company's operating margin is negative, indicating that it is not covering its operating expenses with its gross profit. The company's revenue is concentrated in its domestic market, with no disclosed international operations. The company operates in a single business segment, and its revenue is not diversified across multiple product lines or geographic regions. This lack of diversification increases the company's exposure to domestic economic and regulatory risks. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The company's capital expenditures are negative at CNY -163.98 million, indicating that it is not investing in new assets or expanding its operations. The company's debt-to-equity ratio is 0.15, suggesting that it is not heavily leveraged, but its net cash position is negative after subtracting total debt, indicating that it has more debt than cash on hand. The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The company has a low probability of near-term dilution, with no recent share issuance or shelf registration activity disclosed. However, the company's negative net income and operating cash flow suggest that it may need to raise additional capital in the future to fund its operations. The company's risk assessment does not include any recent filings or transcripts, so there is no additional information on its financial or operational performance.